Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Underdown, Nicola Joy.
Languages: English
Types: Doctoral thesis
Subjects: RM

Classified by OpenAIRE into

mesheuropmc: lipids (amino acids, peptides, and proteins)
This thesis describes work carried out to characterise cardiac responses to cannabinoids. A particular focus of the work was to study the mechanism by which cannabinoids protect hearts from ischaemia-reperfusion injury. Studied in rat isolated right atria, anandamide (an endocannabinoid) induced a limited positive chronotropy. As this response was blocked by indomethacin and not mimicked by methanandamide (a non-hydrolysable analogue), the mechanism of action appears to involve conversion and release of products of cyclooxygenase-2. Conversely, negative chronotropy was observed when baseline rate was elevated by a b-adrenoceptor agonist. The pharmacological profile of this anti-adrenergic response indicated the involvement of CB2 receptors. Potential protection afforded by cannabinoids against rat isolated hearts subjected to ischaemia-reperfusion was studied in two different models. In the first, hearts were subjected to global, no-flow ischaemia-reperfusion with agonists introduced 5 min before ischaemia. The second method subjected hearts to regional ischaemia-reperfusion with agonists introduced 35 min into ischaemia. Antagonists, where used, were present throughout the protocol. In the global, no-flow ischaemia-reperfusion model both anandamide and methanandamide significantly reduced infarction but in the regional ischaemia-reperfusion model only methanandamide significantly reduced infarction. In both models the infarct limiting action was lost in the presence of both the CB1 receptor antagonist SR141716A and the CB2 receptor antagonist SR144528. However, CB1- or CB2-receptor agonists, used alone or in combination, were ineffective at reducing infarct size. These results suggest that neither CB1 nor CB2 receptors, alone or in synergy mediate cardioprotection. These results suggest that one or more novel sites of action, possibly a new cannabinoid receptor subtype, might mediate cardio-protection in rat hearts. These findings demonstrate the potential for cannabinoids to be used as adjuncts to thrombolytics. However, the in vivo effects of cannabinoids in situations of compromised cardiac function needs to be assessed as they could potentially cause excessive hypotension due to peripheral vasodilatation.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • H e a r s e , D.J. & S u t h e r l a n d , F.J. (2000). Experimental models for the study of cardiovascular function and disease. Pharmacol Res, 41, 597-603.
    • H e n q u e t , C ., K r a b b e n d a m , L ., S p a u w e n , J., K a p l a n , C ., L ieb , R., W i t t c h e n , H .-U . & v a n Os, J. (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ, 330,11-.
    • H i l l a r d , C.J. & J a r r a h i a n , A. (2003). Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol, 140, 802-808.
    • H i l l a r d , C.J. & J a r r a h i a n , A . (2000). The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids, 108,123-34.
    • H i l l a r d , C.J., M a n n a , S., G r e e n b e r g , M.J., D iC a m e lli, R., R o s s , R.A., S te v e n s o n , L.A., M u r p h y , V., P e r t w e e , R.G. & C a m p b e ll, W.B. (1999). Synthesis and Characterization of Potent and Selective Agonists of the Neuronal Cannabinoid Receptor (CBI). J Pharmacol Exp Ther, 289,1427-1433.
    • H o w l e t t , A.C. (2002). The cannabinoid receptors. Prostaglandins and other Lipid Mediators, 68-69,619-631.
    • H o w l e t t , A.C., B a r t h , F ., B o n n e r , T.I., C a b r a l , G., C a s e l l a s , P., D e v a n e , W.A., F e l d e r , C.C., H e r k e n h a m , M., M a c k ie , K., M a r t i n , B.R., M e c h o u la m , R. & P e r t w e e , R.G. (2002). International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev, 54,161-202.
    • H u f f m a n , J.W., L i d d le , J., Y u , S., A u n g , M.M., A b o o d , M.E., W ile y , J.L. & M a r t i n , B.R. (1999). 3-(l',r-Dimethylbutyl)-l-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem, 7,2905-14.
    • J a r r a h ia n , A., M a n n a , S., E d g em o n d , W.S., C am pbell, W.B. & H illa r d , C.J. (2000). Structure-Activity Relationships Among N-Arachidonylethanolamine (Anandamide) Head Group Analogues for the Anandamide Transporter. Journal o fNeurochemistry, 74,2597-2606.
    • Ja r r a h ia n , A., W a t t s, V J. & B a r k er , E.L. (2004). D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther, 308, 880-6.
    • J eo n , Y.J., Y a n g , K.H., P u la sk i, J.T. & K a m in sk i, N.E. (1996). Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol Pharmacol, 50, 334-41.
    • Jo n a ssen , A.K., Sa c k , M.N., M jo s, O.D. & Y ello n , D.M. (2001). Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res, 89,1191-8.
    • Jo n sso n , K.-0., V a n d ev o o r d e , S., La m b er t, D.M., T ig er, G. & F o w ler , C.J. (2001). Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. 133, 1263.
    • Jo r d a n , J.E., Z h a o , Z.Q. & V in t en -Jo h a n sen , J. (1999). The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res, 43, 860-78.
    • K o z a k , K.R., P r u s a k ie w ic z , J.J. & M a r n e t t , L J. (2004). Oxidative metabolism of endocannabinoids by COX-2. Current Pharmaceutical Design, 10,659.
    • K o z a k , K .R ., R o w lin s o n , S.W. & M a r n e t t , L J . (2000). Oxygenation of the endocannabinoid, 2-arachidonylglycerol, to glyceryl prostaglandins by cyclooxygenase-2. JBiol Chem, 275, 33744-9.
    • K r u s z k a , K.K. & G r o s s , R.W. (1994). The ATP- and CoA-independent synthesis of arachidonoylethanolamide. A novel mechanism underlying the synthesis of the endogenous ligand of the cannabinoid receptor. JBiol Chem, 269, 14345-8.
    • K u m a r , R.N., C h a m b e r s , W.A. & P e r tw e e , R.G. (2001). Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia, 56,1059-68.
    • M a c L e n n a n , S.J., R e y n e n , P.H., K w a n , J. & B o n h a u s , D.W. (1998). Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br J Pharmacol, 124,619-22.
    • M e c h o u l a m , R., F r id e , E. & Di M a r z o , V. (1998). Endocannabinoids. Eur J Pharmacol, 359,1-18.
    • Mu, J., Z h u a n g , S.Y., K ir b y , M.T., H a m p s o n , R.E. & D e a d w y l e r , S.A. (1999). Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. J Pharmacol Exp Ther, 291, 893-902.
    • M u b a g w a , K. & F l a m e n g , W. (2001). Adenosine, adenosine receptors and myocardial protection: An updated overview. Cardiovascular Research, 52,25.
    • M u k h o p a d h y a y , S., C h a p n ic k , B.M. & H o w l e t t , A.C. (2002). Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol, 282, H2046-54.
    • M u n r o , S., T h o m a s , K.L. & A b u - S h a a r , M. (1993). Molecular characterization of a peripheral receptor for cannabinoids [see comments]. Nature, 365,61-5.
    • M u r r y , C.E., J e n n in g s , R.B. & R e im e r, K.A. (1986). Preconditioning with ischaemia; a delay of lethal cell injury in ischaemic myocardium. Circulation, 74,1124-36.
    • P e r t w e e , R.G. & Ross, R.A. (2002). Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids, 66,101-21.
    • P e s to n ja m a s p , V.K. & B u r s te i n , S.H. (1998). Anandamide synthesis is induced by arachidonate mobilizing agonists in cells of the immune system. Biochim Biophys Acta, 1394,249-60.
    • P e t e r s e n , S., P e t o , V. & R a y n e r , M. (2004). Coronary heart disease statistics. London: British heart foundation.
    • P ip e r, H.M., G a r c i a - D o r a d o , D . & O v iz e , M. (1998). A fresh look at reperfusion injury. Cardiovasc Res, 38,291-300.
    • R ik s e n , N.P., S m its , P. & R o n g e n , G.A. (2004). Ischaemic preconditioning: from molecular characterisation to clinical application - part n. The Journal o f Medicine, 62,409-423.
    • R i n a ld i - C a r m o n a , M., B a r t h , F ., H e a u lm e , M., A lo n s o , R., S h ire , D ., C o n g y , C., S o u b r ie , P., B r e l i e r e , J.C. & L e F u r , G. (1995). Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci, 56,1941-7.
    • S c h w e i tz e r , P. (2000). Cannabinoids Decrease the K+ M-Current in Hippocampal CA1 Neurons. J. Neurosci., 20,51-58.
    • S h ir e , D., C a l a n d r a , B., R in a ld i- C a r m o n a , M., O u s t r i c , D., P e s s e g u e , B., B o n n in - C a b a n n e , O., L e F u r , G., C a p u t, D. & F e r r a r a , P. (1996). Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta, 1307,132-6.
    • S t a a t , P., R i o u f o l , G., P io t, C ., C o t t i n , Y ., C u n g , T .T ., L 'H u illie r , L, A u p e tit, J.- F., B o n n e f o y , E., F in e t, G., A n d r e - F o u e t, X. & O v ize, M. (2005). Postconditioning the Human Heart. Circulation, 112,2143-2148.
    • V a r g a , K., L a k e , K.D., M a r t i n , B.R. & K u n o s , G . (1995). Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. European Journal o fPharmacology, 278,279-283.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article